Apollon Papadimitriou is the founder of IOmx Therapeutics. IOmx Therapeutics has raised $125M in total funding. Latest round: Series B.
Apollon Papadimitriou, Ph.D., is the Chief Executive Officer of iOmx Therapeutics AG, a clinical-stage biotechnology company focused on immuno-oncology treatments for solid tumors. He was named CEO in 2024 after the company strengthened its executive management team following its Series B financing.
Full founder directory · Investor directory · Company funding database · Fundraising library